BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson’s Disease

BlueRock Therapeutics LP announced that the US FDA has granted Fast Track designation for DA01 for advanced Parkinson’s disease. DA01, BlueRock’s PSC-derived dopaminergic neuron therapy, is under evaluation in a Phase I study.